2008/09 Trials Ignite Debate about Regimen for Type 2 Diabetes

摘要

Citations processed in the last two months of 2008 are dominated by diabetes and insulin. At #4, #5, and #9 we have the genetics of this disease; at #6 lies the antidiabetic drug rosiglitazone; still outside the Top Ten but rising at #15 is the New England Journal of Medicine paper by Brunkhorst et al. discussed in the March/April issue (20[2]: 5, 2009); and now we have two newcomers, related trials with differing results but very similar citation records.